· Published by Health Canada · Official notice
This is duplicated text of a letter from the Marketed Health Products and Therapeutic Products Directorates, Health Canada.
Notice about Health Canada advisories
July 10, 2002
Following consultation with Health Canada, all licenced providers of propofol are revising the Contraindication and Dosage and Administration Sections of the Product Monograph for propofol to include: Propofol is contraindicated for the sedation of children 18 years or younger receiving intensive care
The Marketed Health Products and Therapeutic Products Directorates (MHPD and TPD) wish to draw your attention to 6 Canadian reports of a constellation of serious adverse events that occurred in children who received propofol infusions in an ICU setting. Three of the six cases had a fatal outcome, and all cases were characterized by metabolic acidosis, hemodynamic instability, and cardiac conduction abnormalities. Similar findings were first reported in the literature in 1992 in children who had received prolonged propofol infusions in the ICU.Footnote 1 Since the 1992 publication, several similar reports have been published,Footnote 2, Footnote 3, Footnote 4, Footnote 5, Footnote 6 including an article that summarized 18 cases of children who received propofol infusions and suffered serious adverse events, including death.Footnote 7
The identification, characterization, and management of drug-related adverse events is dependent on the active participation of health care professionals in adverse drug reaction reporting programmes. Health care professionals are asked to report any suspected adverse reactions in patients receiving propofol to the Marketed Health Products Directorate at the following address:
Any suspected adverse drug reactions can be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0201C2
Ottawa, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD web site, along with the ADR Guidelines.
Parke, T.J. et al. 1992. British Medical Journal. 305: 613-616.
Cray, S.H., et al. 1998. Critical Care Medicine, 1998: 2087-2092.
Hanna, J.P., and Ramundo, M.L. 1998. Neurology, 50: 301-303.
Mehta, M., et al. 1999. The Lancet. 354: 865-867.
Cannon M.L., et al. 2001. Journal of Neurosurgery, 95: 925-956.
Wolf, A., et al. 2001. The Lancet, 357: 606-607.
Bray, R.J.1998. Paediatric Anaesthesia, 8: 491-499.